Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 059: Tenofovir gel safety and acceptability
NCT00111943Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Implantable Devices, Transdermal Patches, Hydrogel Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tenofovir gel in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Macroscopic evidence of damage to the cervical, vulvar, or vaginal epithelium at 24 weeks. Status: completed.
02
Drugs
tenofovir gel
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00111943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111943.